EssilorLuxottica's vertical monopoly inflates glasses prices by 1,000% while controlling insurance, retail, and manufacturing

healthcare0 views
EssilorLuxottica controls the entire eyewear value chain -- manufacturing frames that cost $10-$30 to produce and selling them for $250-$500+, while simultaneously owning the retail stores (LensCrafters, Sunglass Hut, Pearle Vision, Target Optical), the insurance plan (EyeMed), and the brands (Ray-Ban, Oakley, Persol, Oliver Peoples, plus 20+ licensed brands including Prada, Chanel, Armani, and Burberry). Why it matters: consumers pay 1,000% markups on frames, so the average American spends $200-$600 per pair of glasses, so the 164 million Americans who wear corrective lenses face a cumulative cost burden of tens of billions annually, so low-income households forgo or delay corrective eyewear, so children and adults with uncorrected vision suffer in school performance, workplace productivity, and driving safety. The structural root cause is that EssilorLuxottica (EUR 26.5 billion in 2024 revenue) operates the only vertically integrated business model in eyewear, owning 600+ factories, 128 distribution centers, 13,500+ company-owned stores, and 4,100 franchise locations, which means no competitor can match their end-to-end control, and regulators have not intervened because eyewear is classified as a consumer product rather than a medical necessity subject to price controls.

Evidence

EssilorLuxottica reported EUR 26.5 billion in revenue and EUR 6.7 billion in EBITDA in 2024. The company owns 80% of major eyewear brands, controls ~25% of the global prescription eyeglasses market and over 50% of the lens market. Frame manufacturing cost is $10-$30 per unit (acetate plastic), but average US frame retail price is $231 (Freakonomics, 2022). The 2018 Essilor-Luxottica merger was approved by EU and US regulators with minimal conditions. Consumer Reports found the same frame sold under different brand labels at vastly different price points. The company also owns EyeMed, one of the two dominant US vision insurance plans, creating a conflict of interest where the insurer steers patients to its own retail stores.

Comments